PHS
SNDX icon

PFM Health Sciences’s Syndax Pharmaceuticals SNDX Stock Holding History

PFM Health Sciences’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.59M Sell
118,422
-126,599
-52% -$2.63M 0.22% 83
2026
Q1 		$5.72M Buy
245,021
+2,054
+0.8% +$44.6K 0.52% 60
2025
Q4 		$5.1M Sell
242,967
-13,521
-5% -$236K 0.51% 52
2025
Q3 		$3.95M Buy
+256,488
New +$3.36M 0.3% 56
2025
Q2 		– Sell
-926,424
Closed -$11.4M – 70
2025
Q1 		$11.4M Buy
926,424
+719,553
+348% +$10.1M 0.83% 29
2024
Q4 		$2.73M Sell
206,871
-217,039
-51% -$3.71M 0.17% 67
2024
Q3 		$8.16M Buy
423,910
+36,553
+9% +$755K 0.46% 44
2024
Q2 		$7.95M Sell
387,357
-271,337
-41% -$5.68M 0.39% 50
2024
Q1 		$15.7M Buy
658,694
+63,171
+11% +$1.41M 0.74% 44
2023
Q4 		$12.9M Sell
595,523
-2,119,712
-78% -$32.6M 0.77% 43
2023
Q3 		$39.4M Buy
2,715,235
+542,798
+25% +$10.3M 1.86% 25
2023
Q2 		$45.5M Buy
2,172,437
+225,785
+12% +$4.7M 1.77% 22
2023
Q1 		$41.1M Buy
1,946,652
+132,018
+7% +$3.28M 1.82% 20
2022
Q4 		$46.2M Buy
1,814,634
+525,561
+41% +$12.3M 1.65% 24
2022
Q3 		$31M Buy
1,289,073
+708,305
+122% +$15.9M 1.12% 44
2022
Q2 		$11.2M Sell
580,768
-1,462,609
-72% -$24.4M 0.43% 57
2022
Q1 		$35.5M Sell
2,043,377
-60,135
-3% -$1.01M 1.33% 36
2021
Q4 		$46M Buy
2,103,512
+246,774
+13% +$4.56M 1.57% 28
2021
Q3 		$35.5M Sell
1,856,738
-288,143
-13% -$4.8M 1.04% 41
2021
Q2 		$36.8M Buy
2,144,881
+660,654
+45% +$12.1M 1.15% 33
2021
Q1 		$33.2M Buy
+1,484,227
New +$33.5M 1.01% 39

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

PFM Health Sciences's SNDX Position: Q2 2026 in Review

PFM Health Sciences reduced its Syndax Pharmaceuticals (SNDX) stake by 52% in Q2 2026, selling an estimated $2.63M and leaving 118,422 shares worth $2.59M. The position accounts for 0.22% of the portfolio, ranked #83.

PFM Health Sciences first reported a position in SNDX in Q1 2021 and has held it in 21 quarters since. The position peaked at $46.2M in Q4 2022. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • PFM Health Sciences held 118,422 shares of Syndax Pharmaceuticals worth $2.59M as of Q2 2026.
  • PFM Health Sciences sold 126,599 Syndax Pharmaceuticals shares in Q2 2026, an estimated $2.63M.
  • Syndax Pharmaceuticals made up 0.22% of PFM Health Sciences's portfolio in Q2 2026, its #83 holding.
  • PFM Health Sciences first reported a position in Syndax Pharmaceuticals in Q1 2021 and has held it in 21 quarters since.
  • PFM Health Sciences's Syndax Pharmaceuticals position peaked at $46.2M in Q4 2022.
  • 243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.